Alivus Life Sciences (NSE:ALIVUS) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


NSE:ALIVUS Alivus Life Sciences Ltd NSE:ALIVUS
83 GF Score
Price ₹1,108.30
GF Value ₹1,004.54
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Alivus Life Sciences Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Alivus Life Sciences's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

NSE:ALIVUS vs ZTS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alivus Life Sciences Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Alivus Life Sciences's Margin of Safety % (DCF Earnings Based) falls into.


NSE:ALIVUS
83GF Score
Alivus Life Sciences Ltd NSE:ALIVUS
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?

Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued. The current stock price of ₹1,108.30 is trading 10.3% above its estimated GF Value™ of ₹1,004.54. GuruFocus considers Alivus Life Sciences to be Fairly Valued.

Key valuation signals for NSE:ALIVUS:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: ₹1,004.54 vs. price of ₹1,108.30 (10.3% above fair value)
  • GF Score™: 83/100 with 3 warning signs

No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alivus Life Sciences Business Description

Other Exchanges 543322:India
Address 470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
83GF Score

Get the complete analysis for NSE:ALIVUS

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,108.30
Price
₹1,004.54
GF Value